| dbo:abstract |
تيسامورلين Tesamorelin (الاسم التجاري Egrifta) هو شكل صناعي لمطلق هرمون النمو growth-hormone-releasing hormone (GHRH) الذي يستخدم في علاج المرتبطة بفيروس نقص المناعة البشرية. ويتم إنتاجه بواسطة شركة Theratechnologies, Inc. في كندا. تيسامورلين هو ببتيد اصطناعي يتألف من جميع الأحماض الأمينية 44 لل GHRH عند الإنسان مع إضافة مجموعة حمض العابرة-3-hexenoic. [1] (ar) Tesamorelin (INN) (trade name Egrifta SV) is a synthetic form of growth-hormone-releasing hormone (GHRH) which is used in the treatment of HIV-associated lipodystrophy, approved initially in 2010. It is produced and developed by Theratechnologies, Inc. of Canada. The drug is a synthetic peptide consisting of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group. (en) Tesamorelin (nome commerciale Egrifta ) è un analogo dell'ormone di rilascio della somatotropina umano (GHRH), utilizzato nel trattamento della lipodistrofia HIV-associata . Tesamorelin è prodotto e sviluppato da del Canada. Tesamorelin è un peptide sintetico costituito da tutti i 44 aminoacidi di GHRH umano con l'aggiunta di un gruppo acido trans-3-hexenoic. (it) Tesamorelin (nome comercial Egrifta) é um fármaco aprovado pelo FDA em novembro de 2010 para tratamento da lipodistrofia associada ao HIV. (pt) |
| dbo:alternativeName |
Egrifta SV (en) |
| dbo:casNumber |
218949-48-5 901758-09-6 |
| dbo:chEBI |
63626 |
| dbo:fdaUniiCode |
LGW5H38VE3 MQG94M5EEO |
| dbo:kegg |
D09015 |
| dbo:medlinePlus |
a611035 |
| dbo:pubchem |
16137828 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Tesamorelin.svg?width=300 |
| dbo:wikiPageID |
38106226 (xsd:integer) |
| dbo:wikiPageLength |
9601 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1092839024 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Pruritus dbr:Hypopituitarism dbr:Peptide dbr:List_of_growth_hormone_secretagogues dbc:World_Anti-Doping_Agency_prohibited_substances dbc:Growth_hormone_secretagogues dbc:Recombinant_proteins dbr:Erythema dbr:Organic_compound dbr:Proteolysis dbr:Subcutaneous_injection dbr:HIV-associated_lipodystrophy dbr:Lipolysis dbr:Amino_acid dbc:HIV/AIDS dbr:Growth-hormone-releasing_hormone dbr:International_Nonproprietary_Name dbc:Peptides dbc:Merck_brands dbc:Growth_hormone-releasing_hormone_receptor_agonists dbr:IGF-1 dbr:Dipeptidyl_aminopeptidase |
| dbp:atcPrefix |
H01 (en) |
| dbp:atcSuffix |
AC06 (en) |
| dbp:bioavailability |
≤4% (en) |
| dbp:c |
221 (xsd:integer) |
| dbp:casNumber |
218949 (xsd:integer) 901758 (xsd:integer) |
| dbp:chebi |
63626 (xsd:integer) |
| dbp:chemspiderid |
34982925 (xsd:integer) |
| dbp:eliminationHalfLife |
-2280.0 |
| dbp:excretion |
Renal/proteolysis (en) |
| dbp:h |
366 (xsd:integer) |
| dbp:index2Label |
as salt (en) |
| dbp:kegg |
D09015 (en) |
| dbp:legalStatus |
℞-only (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:medlineplus |
a611035 (en) |
| dbp:metabolism |
dbr:Proteolysis |
| dbp:n |
72 (xsd:integer) |
| dbp:o |
67 (xsd:integer) |
| dbp:pregnancyUs |
X (en) |
| dbp:pubchem |
16137828 (xsd:integer) |
| dbp:routesOfAdministration |
dbr:Subcutaneous_injection |
| dbp:s |
1 (xsd:integer) |
| dbp:smiles |
CCC[C@@H]NC[C@H]NC[C@H]NC[C@@H]NC[C@H]NCCNC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NCCNC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NCCNC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NCC/C=C/CC (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
VQFDKKWXORFBDI-VAVVJCQZSA-N (en) |
| dbp:tradename |
Egrifta SV (en) |
| dbp:unii |
LGW5H38VE3 (en) MQG94M5EEO (en) |
| dbp:width |
250 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Drugbox dbt:Reflist dbt:Cascite dbt:Drugbankcite dbt:Fdacite dbt:Keggcite dbt:Drugs.com dbt:Systemic-hormonal-drug-stub dbt:GH/IGF-1_axis_signaling_modulators |
| dcterms:subject |
dbc:World_Anti-Doping_Agency_prohibited_substances dbc:Growth_hormone_secretagogues dbc:Recombinant_proteins dbc:HIV/AIDS dbc:Peptides dbc:Merck_brands dbc:Growth_hormone-releasing_hormone_receptor_agonists |
| gold:hypernym |
dbr:Form |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:Abstraction100002137 yago:BodySubstance105263850 yago:Chemical114806838 yago:Compound114818238 yago:Hormone105407119 yago:LiquidBodySubstance105397468 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:RecombinantProtein114729633 yago:Relation100031921 dbo:Drug yago:Secretion105404728 yago:Substance100019613 yago:Thing100002452 yago:Unit109465459 yago:WikicatPeptideHormones yago:WikicatRecombinantProteins |
| rdfs:comment |
تيسامورلين Tesamorelin (الاسم التجاري Egrifta) هو شكل صناعي لمطلق هرمون النمو growth-hormone-releasing hormone (GHRH) الذي يستخدم في علاج المرتبطة بفيروس نقص المناعة البشرية. ويتم إنتاجه بواسطة شركة Theratechnologies, Inc. في كندا. تيسامورلين هو ببتيد اصطناعي يتألف من جميع الأحماض الأمينية 44 لل GHRH عند الإنسان مع إضافة مجموعة حمض العابرة-3-hexenoic. [1] (ar) Tesamorelin (INN) (trade name Egrifta SV) is a synthetic form of growth-hormone-releasing hormone (GHRH) which is used in the treatment of HIV-associated lipodystrophy, approved initially in 2010. It is produced and developed by Theratechnologies, Inc. of Canada. The drug is a synthetic peptide consisting of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group. (en) Tesamorelin (nome commerciale Egrifta ) è un analogo dell'ormone di rilascio della somatotropina umano (GHRH), utilizzato nel trattamento della lipodistrofia HIV-associata . Tesamorelin è prodotto e sviluppato da del Canada. Tesamorelin è un peptide sintetico costituito da tutti i 44 aminoacidi di GHRH umano con l'aggiunta di un gruppo acido trans-3-hexenoic. (it) Tesamorelin (nome comercial Egrifta) é um fármaco aprovado pelo FDA em novembro de 2010 para tratamento da lipodistrofia associada ao HIV. (pt) |
| rdfs:label |
تيسامورلين (ar) Tesamorelin (it) Tesamorelin (en) Tesamorelin (pt) |
| owl:sameAs |
freebase:Tesamorelin yago-res:Tesamorelin wikidata:Tesamorelin dbpedia-ar:Tesamorelin dbpedia-it:Tesamorelin dbpedia-pt:Tesamorelin dbpedia-sh:Tesamorelin dbpedia-sr:Tesamorelin dbpedia-tr:Tesamorelin dbpedia-vi:Tesamorelin https://global.dbpedia.org/id/4vUCq |
| prov:wasDerivedFrom |
wikipedia-en:Tesamorelin?oldid=1092839024&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Tesamorelin.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Tesamorelin |
| is dbo:wikiPageRedirects of |
dbr:ATC_code_H01AC06 dbr:ATCvet_code_QH01AC06 dbr:Egrifta dbr:Tesamorelin_acetate |
| is dbo:wikiPageWikiLink of |
dbr:List_of_designer_drugs dbr:HIV-associated_lipodystrophy dbr:ATC_code_H01AC06 dbr:ATCvet_code_QH01AC06 dbr:ATC_code_H01 dbr:Egrifta dbr:Growth-hormone-releasing_hormone_receptor dbr:Growth_hormone_secretagogue dbr:Growth_hormone–releasing_hormone dbr:Tesamorelin_acetate dbr:List_of_drugs:_Te dbr:Steven_Grinspoon |
| is foaf:primaryTopic of |
wikipedia-en:Tesamorelin |
